Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609932 · ClinicalTrials.gov registry record · Phase 1
Effect of IFN-γ on Innate Immune Cells
A Phase 1 study of Chronic Granulomatous Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02609932 is a Phase 1 study of Chronic Granulomatous Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 20 participants, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02609932, a Phase 1 study of Chronic Granulomatous Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.
Conditions Studied
Interventions
- DRUG Administration of drug (Interferon-gamma 1-b) subcutaneously
Study Locations (1)
Colorado
- University of Colorado Denver, Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609932
The ClinicalTrials.gov registry entry for NCT02609932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Granulomatous Disease appearing as the primary indexed condition, and to 1 intervention - of which Administration of drug (Interferon-gamma 1-b) subcutaneously is the first listed.
NCT02609932 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02609932 about?
NCT02609932 is a clinical study titled "Effect of IFN-γ on Innate Immune Cells". The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The i...
What is the current status of trial NCT02609932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-07. Estimated completion is 2019-02.
What conditions does trial NCT02609932 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease.
What interventions are being tested in trial NCT02609932?
The interventions under investigation include: Administration of drug (Interferon-gamma 1-b) subcutaneously (DRUG).
Who is sponsoring clinical trial NCT02609932?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02609932 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
RECRUITING · Phase 1
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
ACTIVE NOT RECRUITING · Phase 1
-
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
COMPLETED · Phase 1
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.